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Abstract
Increasing evidence indicates that bacterial quorum sensing (QS) signals are important mediators of immunomodulation.
However, whether microbes utilize these immunomodulatory signals to maintain infection remain unclear. Here, we show
that the Pseudomonas aeruginosa QS-regulated molecule 2-amino acetophenone (2-AA) modulates host immune responses
in a manner that increases host ability to cope with this pathogen. Mice treated with 2-AA prior to infection had a 90%
survival compared to 10% survival rate observed in the non-pretreated infected mice. Whilst 2-AA stimulation activates key
innate immune response pathways involving mitogen-activated protein kinases (MAPKs), nuclear factor (NF)-kB, and pro-
inflammatory cytokines, it attenuates immune response activation upon pretreatment, most likely by upregulating anti-
inflammatory cytokines. 2-AA host pretreatment is characterized by a transcriptionally regulated block of c-JUN N-terminal
kinase (JNK) and NF-kB activation, with relatively preserved activation of extracellular regulated kinase (ERK) 1/2. These
kinase changes lead to CCAAT/enhancer-binding protein-b (c/EBPb) activation and formation of the c/EBPb-p65 complex
that prevents NF-kB activation. 2-AA’s aptitude for dampening the inflammatory processes while increasing host survival
and pathogen persistence concurs with its ability to signal bacteria to switch to a chronic infection mode. Our results reveal
a QS immunomodulatory signal that promotes original aspects of interkingdom communication. We propose that this
communication facilitates pathogen persistence, while enabling host tolerance to infection.
Citation: Bandyopadhaya A, Kesarwani M, Que Y-A, He J, Padfield K, et al. (2012) The Quorum Sensing Volatile Molecule 2-Amino Acetophenon Modulates Host
Immune Responses in a Manner that Promotes Life with Unwanted Guests. PLoS Pathog 8(11): e1003024. doi:10.1371/journal.ppat.1003024
Editor: Barbara I. Kazmierczak, Yale University, United States of America
Received May 21, 2012; Accepted September 26, 2012; Published November 15, 2012
Copyright:  2012 Bandyopadhaya et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by Shriners research grant #87100 to LGR. The funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: rahme@molbio.mgh.harvard.edu
¤ Current address: Cincinnati Children’s Hospital and Medical Center, Cincinnati, Ohio, United States of America.
. These authors contributed equally to this work.
Introduction
Host-pathogen interactions are characterized by an antagonistic
interplay between bacterial and host factors. The overall success of
a pathogen depends on the efficacy of its virulence factors, anti-
immune weapons, and the immune status of the host. Secreted
microbial products, which include many virulence factors, play a
critical role in the outcome of this antagonistic interaction.
Bacterial quorum sensing (QS) regulates many of these products
[1], [2]. QS is a communication system widely utilized by bacteria
to perceive and promote collective behaviors that depend on
population density signaling. This cell density-dependent commu-
nication system is achieved through the production and regulation
of low-molecular-weight, excreted signal molecules [1], [3] as a
means for pathogens to activate virulence factors [4] critical for
infecting mammals [4–6]. Several such signal molecules are
becoming more appreciated recently as important anti-immune
weapons and mediators of inter-kingdom antagonistic relations
[7].
One of the best characterized QS systems is that of the
recalcitrant Gram-negative bacterium Pseudomonas aeruginosa [8],
[9]. This opportunistic pathogen defies eradication by antibiotics
and is an exemplar of bacteria that produce clinically problematic
acute and chronic infections. It causes particularly difficult to treat
infections in people with cystic fibrosis (CF), burn wounds, trauma,
and compromised immune systems [10], [11]. P. aeruginosa controls
the gene expression of many virulence factors through three QS
systems: LasR, RhlR, and MvfR (PqsR) [9]. LasR and RhlR are
activated by the N-acyl-homoserine lactone (AHL) signaling
molecules N-3-oxododecanoyl homoserine lactone (3-oxo-C12-
HSL) and N-3-butanoyl-DL-homoserine lactone (C4-HSL) [9].
Meanwhile, MvfR (PqsR) is activated by the 4-hydroxy-2-
alkylquinolines (HAQs) signaling molecules PQS (2-heptyl-3,4-
dihydroxyquinoline (Pseudomonas Quinolone Signal) and HHQ
(4-hydroxy-2-heptylquinoline) [5], [6], [8], [12]. In addition to
their role as QS signal molecules, AHLs and HAQs also modulate
inflammation and immune responses in mammals [7], [13]. The
3-oxo-C12-HSL signal molecule inhibits dendritic cell and T-cell
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of macrophages and monocytes to respond to a range of Toll-like
receptor (TLR) agonists through disruption of nuclear factor (NF)-
kB signaling [13]. 3-oxo-C12-HSL is a strong inducer of pro-
inflammatory cytokines such as interleukin (IL)-6 and IL-8 in
airway epithelial cells, lung fibroblasts, and macrophages, and is
an enhancer of neutrophil chemotaxis [18]. Although it is known
to upregulate inflammatory mediators through NF-kB [19] and
extracellular regulated kinase (ERK)1/2 pathways [20], 3-oxo-
C12-HSL does not activate the p38 mitogen-activated protein
kinase (MAPK) pathway in lung epithelial cells [19]. Vikstro ¨met al.
provided evidence that 3-oxo-C12-HSL specifically activates the
p38 MAPK pathway in human macrophages, without activating
the ERK1/2 signaling cascade [21]. Taken together, these data
suggest that 3-oxo-C12-HSL suppresses key immune networks
responsible for bacterial clearance, while simultaneously enhanc-
ing inflammatory pathways that promote P. aeruginosa pathogen-
esis. Relative to AHLs, HAQs have been investigated much less
extensively. It has been reported that the HAQs signals PQS and
HHQ do not affect apoptosis, but rather down-regulate host
innate immune responses through the NF-kB pathway [22], [23].
Collectively, P. aeruginosa QS secreted small molecules serve
multiple purposes in their effort to enhance bacterial pathogenesis
and secure infection.
Immune response activation is a critical step in host resistance to
infection and pathogen elimination. Perhaps the best studied
defense signaling pathways are those that involve TLRs, which
bind to microbial products, leading to the activation of innate
immune responses critical for subsequent adaptive immune
responses [24], [25]. Through a series of intracellular signaling
molecules, microbial associated molecules activate NF-kB [26]
and MAPKs, including ERK1/2, p38 kinase, and c-JUN N-
terminal kinase (JNK) [27]. As regulators of several transcription
factors, including NF-kB [28], [29], activator protein-1 (AP-1),
and CCAAT/enhancer-binding protein (c/EBP), these kinases
play an important role in initiating the expression of genes
involved in immune responses [30], [31]. The rapid activation of
diverse signaling pathways induces immune cells to express
downstream genes encoding pro-inflammatory cytokines [32],
which then alert the innate immune system. Such immune
activation is required for pathogen elimination [33–36] However,
microbial pathogens can actively inhibit activation of innate
immune responses [37–39] thus favoring the establishment of a
persistent lifestyle that may lead to chronic infection. Chronic
infections are generally established following an acute infection
period involving activation of both the innate and acquired
immune systems [40]. During host tolerance—defined as coping
with a pathogenic encounter without a consequent reduction in
fitness [41–46] —the host’s strategy is to avoid a harmful excessive
inflammatory response [47], [48]. However, unfortunately for the
host, this strategy may enable pathogen persistence.
Although recognition of the exploitation of host signaling
pathways by QS regulated excreted molecules is increasing, it
remains unclear whether pathogens employ QS to cause chronic
infection and whether the host fights infection through the
detection of these molecules. We showed recently that, through
the control of the QS-regulated small volatile aromatic molecule 2-
amino-acetophenon (2-AA) [49], the QS transcription factor
MvfR promotes the emergence of P. aeruginosa phenotypes, thereby
favoring pathogen adaptation and a chronic presence of P.
aeruginosa [49]. 2-AA, which is responsible for P. aeuriginosa’s sweet
‘‘grape-like’’ odor in culture and human infections [50], is one of
the most abundant MvfR-controlled low molecular weight QS
molecules produced and excreted by pathogen. This molecule has
been proposed as a biomarker for P. aeruginosa colonization in burn
wounds [50] and chronically infected CF lung tissues [51].
The presence of 2-AA in infected human tissues together with
its ability to signal bacterial changes that favor chronic infection
[49] raise the question of whether this molecule modulates host
immune responses, and whether such modulation may favor the
long-term presence of the pathogen. Thus, in the present study, we
investigated 2-AA’s possible immunomodulatory role. Animal and
ex vivo studies were conducted to explore the impact of 2-AA on
inflammatory processes as well as to assess 2-AA’s effects on the
activation of immune effectors and on the ability of the mice to
tolerate the long-term presence of P. aeruginosa.
Results
2-AA pretreatment leads to increased survival of mice
and bacterial persistence in infected tissues
To determine if 2-AA modulates host immune responses, we
assessed the susceptibility of 2-AA pretreated mice to P. aeruginosa
infection (strain PA14) using a burn and infection (BI) model [52].
We observed a time-interval dependent protective effect of host
pre-exposure to 2-AA. Mice pretreated with 2-AA 6 h or 1 d pre-
BI showed no protection; the animals died at the same rate as
untreated BI controls (Fig. 1A). However, mice injected 4 d pre-BI
had a survival rate of 90%, which was remarkably better than the
10% rate observed in untreated BI controls (Fig. 1A). Pretreatment
with 2-AA 2 d, 8 d, or 30 d before BI had more modest benefits;
these mice showed survival rates of 50%.
Animals pretreated with the 2-AA metabolite 3OH-2-AA [53]
4 d prior to BI (Fig. 1B) showed a lesser degree of protection (60%
survival at 72 h) relative to animals pretreated with 2-AA,
indicating that the robust effect observed with 2-AA could not
be attributed to the 3OH-2-AA metabolite. Pretreatment with the
2-AA structural analogs 4-amino acetophenone (4-AA), 2-nitro-
acetophenone (2-NA), or methyl anthranilate (MA) (Fig. S2)
Author Summary
Pseudomonas aeruginosa, a recalcitrant Gram-negative
opportunistic pathogen, defies eradication by antibiotics
and exemplifies current highly problematic pathogens that
often cause untreatable acute or chronic infections. There
is increasing evidence that small molecules excreted by
bacterial pathogens may impact human health by affect-
ing functions including immunity. Although such small
molecules in favor of acute infections have been reported,
small molecules that may impact immune responses in
pathogens’ favor of maintaining a chronic infection have
not. We recently published work showing that the P.
aeruginosa small molecule 2-amino acetophenone (2-AA)
promotes bacterial phenotypic and genetic changes
associated with chronic infection. Here, we provide
evidence that this diagnostically important small volatile
molecule dampens the host inflammatory process trig-
gered by infection, thus favoring chronic infection. 2-AA
limits the inflammatory response by balancing the
secretion of pro- and anti-inflammatory mediators in vivo,
as well as in vitro, while improving survival against P.
aeruginosa infection. The ability of 2-AA to dampen
inflammatory processes, while increasing host survival
and pathogen persistence, suggests that this molecule
promotes host tolerance to infection. Our findings provide
novel insights into pathogen weapons and mechanisms
used to enable long-term bacterial presence in infected
tissues.
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delivered 4 d before BI) relative to that observed with 2-AA (90%)
(Fig. 1B). These findings show that 2-AA provides markedly
stronger protection than structurally similar molecules, indicating
that the 2-AA effect is relatively specific.
The survival benefit yielded by 2-AA pretreatment cannot be
attributed to the reduced bacterial proliferation since 2-AA
pretreatment significantly increased PA14 loads at the wound site
7 d after BI compared to untreated controls (Fig. 1C). Moreover
using a chronic wound infection model [54], we showed that
animals co-inoculated with 2-AA and bacteria maintained high
PA14 loads (mean of ,1610
4 colony forming units [CFU]/g of
tissue) in infected tissues 11 d post-infection, whereas the untreated
animals almost completely cleared the bacteria (Fig. 1D). These
results suggest that 2-AA supports the long term presence of
bacteria.
2-AA modulates the inflammatory response in vivo
We proceeded to examine the mechanism by which 2-AA can
reduce mortality against P. aeruginosa without eliminating bacterial
load in mice. We found that 2-AA treatment 4 d pre-BI reduced
serum levels of the pro-inflammatory cytokines IL-1a, IL-1b, IL-4,
interferon (IFN)c, and tumor necrosis factor (TNF)-a, compared to
untreated BI mice, while augmenting secretion of the anti-
Figure 1. 2-AA enhances survival following BI. (A) Mice were injected with 2-AA (6.75 mg/kg mice) or PBS 6 h (n=20), 2 d (n=20), 4 d (n=20),
8 d (n=20), or 30 d (n=20) prior to BI with PA14. The data shown are averages of two independent experiments. Significance of survival rate
differences was determined using the Kaplan-Meier method, with a hazard ratio of 1.8932 (95% CI, 1.0664–6.0718). Infection (2) drastically reduced
survival relative to (2-AA W/O BI) controls (p=0.03). Delivery of 2-AA 4 d before BI (red) had a particularly powerful influence on survival versus mice
not pretreated with 2-AA (p=0.03). A less remarkable, but still significant, survival benefit was also observed in BI mice pre-exposed to 2-AA 6 h, 2 d,
8 d, or 30 d before BI (all p=0.03 vs. non-infected 2-AA exposed controls). (B) Relative to the effects observed with 2-AA (n=20), 4 d pretreatment
with the 2-AA analogs 4-AA (n=8; p=0.03), 2-NA (n=8; p=0.03), or MA (n=8; p=0.03), or the 2-AA metabolite 3OH-2-AA (n=8; p=0.03) prior to
PA14 infection had weak, though still statistically significant, positive effects on survival after infection. Significance of survival rate differences was
calculated as in A. (C) Bacterial loads in the local muscle 7 d post-BI were significantly higher in mice pretreated with 2-AA 4 d before BI (n=7) than in
control mice subjected to BI without 2-AA pretreatment (n=7; p,0.05, Kruskal-Wallis test). CFU data are presented on a log10 scale. (D) CFU counts at
the site of infection in mice 11 d postinfection. The 2-AA treated mice showed proliferation and higher counts than mice that were not treated with
2-AA. (n=6; p,0.001, Kruskal-Wallis test). CFU data are presented on a log10 scale.
doi:10.1371/journal.ppat.1003024.g001
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ment on IL-6, IL-2, and IL-12 were observed (data not shown).
These results suggest that 2-AA pretreatment may reduce
inflammation by maintaining a balance between pro- and anti-
inflammatory processes.
Additionally, we found that pretreating mice with 2-AA 4 d
prior to infection provided protection against severe inflammation
in an acute lung infection model [55]. Lung histopathology was
compared with untreated control mice (Fig. 3A). Untreated mice
infected with PA14 rapidly developed extensive inflammation
within the lungs, as evidenced by a red hepatization of the lung
tissues 24 h after infection. After 48 h, there was extensive
progression of the pneumonia with the formation of bacteria-
filled necrotic foci throughout the lung parenchyma (Fig. 3B). In
sharp contrast, lung inflammation was markedly attenuated in
mice given 2-AA 4 d prior to being infected (Fig. 3C).
2-AA pretreatment represses 2AA-induced NF-kB
activation pathway in mouse macrophages
We examined how 2-AA affects the innate immune system ex
vivo in a mouse macrophage cell line stably expressing a NF-kB-
luciferase transcriptional fusion gene. 2-AA stimulation produced
a dose-dependent, transient NF-kB activation that peaked at about
4 h (Figs. 4A–B, S1A). Interestingly, this NF-kB activation effect of
2-AA stimulation was dampened in macrophages pretreated with
2-AA for 48 h (Fig. 4B). This dampening effect was not due to 2-
AA cytotoxicity (see data in Fig. S3). Furthermore, the effect was
found to be related to 2-AA since pretreatment of macrophages
with the 2-AA analogs 3-amino acetophenone (3-AA) (data not
shown) and 4-AA (Fig. 4C) did not modify 2-AA induced NF-kB
activation.
Stimulation of macrophages with 2-AA caused a rapid
degradation of the NF-kB inhibitor I-kBa within 15 min, and
cleavage of the NF-kB inhibitor I-kBb by 60–120 min. In
contrast, 2-AA-pretreated macrophages maintained high levels of
I-kBa and I-kBb upon stimulation (Fig. 4D). Western blot analysis
further showed that, in 2-AA pretreated cells, phosphorylation of
the p65 subunit of NF-kB, which enables I-kBa release and
proteolysis [56], was reduced relative to that in non-pretreated
cells (Fig. 4E & S5A) Additionally, a concentration-dependent
increase in DNA binding of activated NF-kB p65 was observed in
non-pretreated macrophages upon 2-AA stimulation, whereas this
DNA binding was reduced in 2-AA pretreated cells (Fig. 4F). In
Figure 2. 2-AA pretreatment modulates the pro-inflammatory response in vivo. Multiplex ELISA showed that BI induced surges in serum
levels of IL-1a, IL-1b, IL-4, IL-10, IFN-c, and TNF-a 24 h post-BI, and that 2-AA pretreatment delivered 4 d before BI attenuated the surges in IL-1a, IL-
1b, IL-4, IFN-c, and TNF-a, while augmenting the surge in IL-10 (n=4 per group). Mean values calculated from 2–4 replicate experiments are depicted
with SD error bars. *p,0.05 vs. naı ¨ve; **p,0.05 vs. BI (Student’s t test).
doi:10.1371/journal.ppat.1003024.g002
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(Fig. 4G). Taken together, these findings demonstrate that 2-AA
pretreatment represses NF-kB activity. As shown in Figure S4,
NF-kB activity was also dampened in 2-AA pretreated macro-
phages stimulated with other pathogen-associated molecules, such
as LPS and peptidoglycan (PGN), providing additional support for
the validity of our observations with 2-AA.
2-AA pretreatment down-regulates pro-inflammatory
cytokines while upregulating anti-inflammatory cytokine
production in mouse macrophages
Since NF-kB regulates the production of pro-inflammatory
mediators [57], we hypothesized that 2-AA pretreatment would
reduce the production of pro-inflammatory cytokines, as seen in
the in vivo experiments presented above (Fig. 2). Compared to 2-
AA non-pretreated macrophages, 2-AA pretreated cells showed a
decreased production of the pro-inflammatory cytokines TNF-a
and IFN-c (Fig. 5A and 5B), and an increased release of the anti-
inflammatory cytokine TGF-b following stimulation with 0.2 or
0.4 mM 2-AA (Fig. 5C).
2-AA pretreatment modulates MAPK signaling
components of innate immunity
We explored the effects of 2-AA stimulation and pretreatment
on activation of ERK1/2, JNK, p38 MAPK, c-Jun, and c-Fos,
which are essential components of innate immune signaling
pathways in macrophages [58], [59]. A transient increase in
phosphorylated p38 and JNK1/2 MAPKs was observed 5–15 min
after 2-AA stimulation (Fig. 6A & B, S5B & C). This increase was
blocked in 2-AA pretreated macrophages (Fig. 6A & B, S5B & C).
2-AA stimulation did not activate ERK1/2 in 2-AA naı ¨ve cells,
but did induce ERK1/2 phospholyration in 2-AA pretreated cells
(Fig. 6C & S5D).
TransAM assays demonstrated that 2-AA stimulation of 2-AA
naı ¨ve cells resulted in phosphorylation, and therefore activation, of
the AP-1 family transcription factors c-Fos and c-Jun, enabling
them to bind to the AP-1 promoter element. This 2-AA
stimulation-induced binding of c-Fos and c-Jun was dampened
in pretreated cells (Fig. 6D & E). These data fit with the
aforementioned down-regulation of JNK and p38 phosphorylation
observed in 2-AA pretreated macrophages. Pretreatment with the
2-AA analog 4-AA did not alter c-Fos and c-Jun binding to the
AP-1 element (Fig. S6).
c/EBPb over-expression and formation of the c/EBPb-p65
complex supports the inhibition of p65 phosphorylation
in 2-AA pre-treated cells
To investigate the possible role of ERK1/2 in dampening of
inflammation after 2-AA pretreatment, we examined c/EBPb and
NF-kB activation [60]. We found that expression of the c/EBPb,
which functions downstream of the MEK-ERK1/2 pathway [60],
was markedly increased in 2-AA pretreated macrophages follow-
ing 2-AA stimulation relative to the expression observed in non-
pretreated, stimulated macrophages (Fig. 7A). Moreover, in the
presence of a MEK inhibitor, c/EBPb expression was blocked and
2-AA pretreated cells showed the expected down-regulation of
ERK1/2 and c/EBPb (Fig. 7B).
We proceeded to examine whether increased c/EBPb expres-
sion contributes to the prevention of NF-kB activation in 2-AA
pretreated cells. As shown in Figure 7C, 2-AA stimulation resulted
in phosphorylation of the NF-kB p65 subunit at ser 536 in the
trans-activating domain (TAD)-1 in non-pretreated cells, but this
phosphorylation was abolished in 2-AA pretreated cells. More-
over, co-immunoprecipitation (IP) studies supported the notion
that c/EBPb/p65 complex formation occurs in 2-AA pretreated
cells only (Fig. 7C). Formation of the c/EBPb-p65 complex
prevents subsequent p65 activation.
2-AA-mediated silencing is controlled, at least in part, at
the transcriptional level
Because 2-AA stimulation alone caused activation of NF-kB and
transcriptional targets of NF-kB can inhibit JNK activation [59],
we used NF-kB signaling inhibitors, at the time of 2-AA
pretreatment, to examine the possibility that activation of NF-kB
may account for 2-AA mediated silencing. We found that JNK
phosphorylation was sustained after stimulation with 2-AA in the
presence of NF-kB inhibitors (Fig. 8A & B). Further exposure of
macrophages to the transcription inhibitor actinomycin D at the
time of 2-AA pretreatment also partially restored phosphorylation
of JNK in response to subsequent 2-AA stimulation (Fig. 8C),
Figure 3. Histopathology of lung tissues after 2-AA treatment. (A) Control healthy (non-infected) lung tissue 4 d after 2-AA treatment. (B)
Inflammatory cell infiltration with large areas of consolidation in lung parenchyma 48 h after infection with PA14 (Black arrows indicate the infiltration
and necrotic foci). (C) Lack of infiltration 48 h after PA14 infection in the lungs of mice pretreated with 2-AA 4 d prior to BI.
doi:10.1371/journal.ppat.1003024.g003
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PLOS Pathogens | www.plospathogens.org 5 November 2012 | Volume 8 | Issue 11 | e1003024Figure 4. 2-AA pretreatment modulates activation of the NF-kB pathway in mouse macrophages. (A) Schematic of 2-AA treatment.
Macrophages were left untreated (No Pre) or pretreated with 0.8-mM 2-AA or 4-AA for 48 h (2-AA/4-AA Pre). The untreated and 2-AA pretreated cells
were then stimulated with 0.2 mM, 0.4 mM, or 2.0 mM 2-AA (for experiment in B) or 4-AA (for experiment in C). (B) Pretreatment with 2-AA blocked
Bacterial QS Mediated Immunomodulation
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effect observed is controlled, at least in part, at the transcriptional
level.
Discussion
This study demonstrates the contribution of the low-molecular-
weight QS molecule 2-AA in the modulation of mammalian
innate-immune signaling pathways. This is the first study to show
that this long-known [61], but scarcely studied, P. aeruginosa
molecule modulates host responses. Unlike other immune-
suppressing QS molecules, which promote activation of virulence
functions leading to acute infection [8], [62], herein we showed
that 2-AA minimizes activation of immune effectors and increases
survival of infected animals, while permitting a long-term presence
of the pathogen in vivo. Our cytokine profiling results suggest that
2-AA pretreatment limits inflammation by dampening pro-
inflammatory cytokine activation. These data support the notion
that 2-AA pretreatment protects host animals by balancing pro-
and anti-inflammatory cytokine levels. 2-AA’s ability to dampen
host inflammation may be critical for both host survival and long-
term survival of 2-AA secreting bacteria in host tissues.
Chronic infection is normally established after an acute
infection period involving activation of both the innate and
acquired immune systems. The ability of a host to tolerate a
bacterial presence without negatively affecting the pathogen’s
fitness is particularly important since 2-AA eventually decreases
the expression of many acute P. aeruginosa virulence related genes
[49], making the pathogen vulnerable to clearance. Importantly,
2-AA not only silences the MvfR virulence regulon [49], but also
promotes bacterial changes that favor long-term survival in a
dynamic host environment. Thus, considered together with our
prior published findings, the present results strongly suggest that 2-
AA may serve a dual purpose: (1) to promote bacterial changes
that favor chronic adaptability of the pathogen and (2) to suppress
innate immune responses, allowing successful bacterial mainte-
nance in host tissues.
The 2-AA mediated concomitant regulation of pro-inflamma-
tory and anti-inflammatory cytokines resembles the endotoxin
tolerance promoted by lipolysaccharide (LPS) [63], [64]. The
decreased mortality observed in LPS-pretreated animals, howev-
er, is accompanied by a more efficient bacterial clearance [65],
[66], rather than a long-lasting bacterial presence as occurred in
our 2-AA-pretreated animals. Recently, Khajanchi et al. showed
that animals pretreated with the QS molecule 3-oxo-C12-HSL
had reduced levels of pro-inflammatory cytokines and cleared
Aermonas hydrophila bacteria without tissue damage [67]. Con-
versely, we found that 2-AA pretreatment not only did not clear
P. aeruginosa bacteria or affect its growth, but rather resulted in a
higher bacterial load relative to that in non-pretreated mice.
These findings strongly suggest that 2-AA’s effect on host
responses may enable the long-term presence of P. aeruginosa.A
similar phenomenon was observed in plant infections involving
the virulence factor XopD, which promotes Xanthomonas campestris
pathovar vesicatoria growth in planta, while reducing host defense
responses and delaying the development of disease symptoms
[68].
Several recent studies have shown down-regulation of NF-kB,
ERK1/2, JNK, and p38 MAPK activation in endotoxin-tolerant
mouse macrophages [63], [69]. Although clarifying the exact
molecular mechanism mediating the 2-AA pretreatment response
will require further investigation, our findings show that 2-AA
negatively impacts activation of NF-kB, JNK, and p38 MAPK,
but increases ERK activation in pretreated cells. Based on the
presented findings, we propose the model depicted in Figure 9.
Briefly, 2-AA pretreatment may trigger a tolerance phenomenon
to subsequent 2-AA challenges, leading to a dramatically increased
survival rate of P. aeruginosa infected mice. Our findings further
suggest that these effects are achieved by a block in MAPK and
NF-kB activation, and activation of ERK1/2, leading to c/EBPb
activation and formation of the c/EBPb-p65 complex that
NF-kB activation relative to cells not pretreated with 2-AA (0.8 mM). (C) NF-kB was activated by 2-AA analog 4-AA in 4-AA pretreated and not
pretreated cells. Mean values calculated from 2–4 replicate experiments are depicted with SD error bars. (D and E) Following stimulation with 2-AA
(0.4 mM), cellular extracts prepared from not pretreated and 2-AA pretreated macrophages. Western blots of I-kBa and I-kBb degradation (D) and
phosphorylation of NF-kB subunit p65 (E). Loading was normalized relative to mouse b-actin. (F and G) A TransAM NF-kB assay showed binding of
NF-kB p65 and p50 with the NF-kB promoter in not pretreated and 2-AA pretreated cells following stimulation with 2-AA. Mean values calculated
from three replicate experiments are depicted with SD error bars. (p,0.05, Student’s t test).
doi:10.1371/journal.ppat.1003024.g004
Figure 5. 2-AA pretreatment alters the expression of pro- and
anti-inflammatory cytokines upon 2-AA stimulation in macro-
phages. Levels of TNF-a (A), IFN-c (B), and TGF-b (C), following 6 h
stimulation of 2-AA as measured by ELISA. The experiments were
performed in triplicate and the results are expressed as means 6 SD.
(p,0.05, one-way ANOVA).
doi:10.1371/journal.ppat.1003024.g005
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PLOS Pathogens | www.plospathogens.org 7 November 2012 | Volume 8 | Issue 11 | e1003024Figure 6. 2-AA pretreatment alters activation of the MAPKs and AP-1 in macrophages upon 2-AA stimulation. Western blotting of
cellular extracts with phospho-specific antibodies after 48 h pretreatment with 2-AA (0.8 mM) followed by stimulation with 0.4 mM 2-AA (A) p38
MAPK, (B) JNK1/2 and (C) ERK1/2. One representative experiment (out of three) is shown. Loading was normalized relative to mouse b-actin. A
TransAM AP-1 transcription factor assay after 48-h pretreatment with 2-AA (0.8 mM) followed by stimulation with 2-AA, showing the binding of c-Fos
(D) and c-Jun (E) to AP-1 promoter. Mean values calculated from three replicate experiments are depicted with SD error bars. (p,0.05, Student’s t
test).
doi:10.1371/journal.ppat.1003024.g006
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2-AA strongly increased p65 phosphorylation in non-pretreated
macrophages, but not in 2-AA pre-treated cells. It is well known
that pro-inflammatory stimuli induce phosphorylation of NF-kB
subunit p65, which is thought to increase the transactivation
potential of p65 [70–72] and that suppression of p65 phosphor-
ylation coincides with inhibition of I-kBa degradation [56].
Moreover, we showed that pretreatment with 2-AA induces the
expression of ERK1/2 and in turn c/EBPb, which binds directly
to p65, resulting in c/EBPb-p65 complex formation. ERK1/2
induction down-regulates NF-kB mediated transcription [29] and
initiates post-transcriptional modification of c/EBPb. This mod-
ification leads to a conformational change in c/EBPb that
unmasks its bZIP heterodimerzation domain [30], thereby
enabling formation of the c/EBPb-p65 complex [73], [74].
Formation of the c/EBPb-p65 complex may mechanically alter
interactions between NF-kB p65 and its inhibitors by blocking
specific phosphorylation sites [75], [76], thereby enabling c/EBPb
to form an inhibitory box [77] in 2-AA pretreated cells. Since c/
EBPb is involved in immune modulation [31], c/EBPb-p65
Figure 7. Inhibition of p65 phosphorylation in 2-AA pretreated cells is accompanied by de novo formation of c/EBPb-p65
complexes. (A) Western blots of cellular extracts incubated with c/EBPb from macrophages that had been incubated for 48 h with 0.8 mM 2-AA (2-
AA Pre) or plain medium (No Pre) and subsequently stimulated with 0.4 mM 2-AA for the indicated time periods. (B) Western blot showing inhibition
of ERK1/2 and c/EBPb in 2-AA pretreated cells in the presence of MEK1 inhibitor PD98059 (1 mM, 5 mM, or 10 mM). Loading was normalized relative to
mouse b-actin. (C) In cells treated as above, c/EBPb-p65 complex formation monitored by IP followed by immunoblotting with anti-c/EBPb or anti-
p65 antibodies.
doi:10.1371/journal.ppat.1003024.g007
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PLOS Pathogens | www.plospathogens.org 9 November 2012 | Volume 8 | Issue 11 | e1003024Figure 8. Transcription and NF-kB inhibitors can block the effects of 2-AA pretreatment. Western blots showing phosphorylation of JNK1/
2 in 2-AA pretreated or untreated cells along with CAPE (1.5 mM) (A), MG-132 (1 mM) (B), and actinomycin D (1 mM) (C) following 0.2 mM or 0.4 mM 2-
AA stimulation. Loading was normalized relative to mouse b-actin. One representative experiment (of three) is shown for JNK1/2.
doi:10.1371/journal.ppat.1003024.g008
Figure 9. Proposed model for 2-AA immunomodulatory mechanisms. In naı ¨ve cells (left), stimulation with 2-AA induces activation of NF-kB,
which leads to the phosphorylation and degradation of I-kBa, releasing the NF-kB dimers p65 and p50. 2-AA also induces the p38 MAPK and JNK
pathways to stimulate c-Jun and c-Fos. Activation of MAPK and NF-kB pathway upregulates pro-inflammatory genes. In contrast, in 2-AA pretreated
cells (right) over-expression of ERK1/2 activates C/EBPb, which binds directly to p65, resulting in c/EBPb-p65 complex formation, and preventing 2-AA
induced phosphorylation of p65 upon 2-AA stimulation. This interaction inhibits NF-kB mediated transactivation. The activation of JNK and p38 MAPK
are repressed in 2-AA pretreated cells. All together, repression of the p38 MAPK, JNK, and NF-kB pathways abrogates the activation of pro-
inflammatory mediators.
doi:10.1371/journal.ppat.1003024.g009
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expression of pro-inflammatory cytokines.
Interestingly, LPS pretreated cells also exhibit reduced NF-kB
activation and binding activity, accompanied by decreased
degradation of IkBa and IkBb [63]. Thus, as shown in Figure 9,
a 2-AA induced tolerance in murine macrophages ex vivo may be
achieved by inhibiting activation of both NF-kB and AP-1 factors
(i.e. c-Jun and c-Fos). Additionally, our observations that
actinomycin D and NF-kB inhibitors can block 2-AA pretreatment
effects on JNK activation are consistent with the idea that 2-AA
works at the transcriptional level and requires de novo protein
synthesis. We also showed that 2-AA pretreated macrophages were
not fully responsive to other pathogen-associated molecules, such
as LPS and peptidoglycan (PGN) (Fig. S4). Therefore dampening
of immune signaling pathways by other pathogen associated
molecules [78], [79] or endogenous danger signals—such as pro-
inflammatory cytokines [80], heat shock proteins [81], [82], and
hayluran [83]—might also play a role in infection-induced
immunosuppression and the establishment of chronic/persistent
bacterial infections. It remains to be determined whether these
other agents also improve host survival in vivo and modulate
defense mechanisms in the context of an active infection.
Several mechanisms may collectively contribute to 2-AA
mediated tolerance in vivo and ex vivo. Firstly, genes encoding
pro-inflammatory cytokines are inactivated to limit tissue damage.
Meanwhile, anti-inflammatory mediators that do not disrupt host
tissue physiology provide protection from inflammation and
pathogen-induced damage. Our data indicate that selective and
transient inactivation of immune mediators at the intracellular
signaling level may play an important role in 2-AA induced host
tolerance.
In conclusion, our results strongly support the notion that 2-AA
produces immunomodulatory effects that enhance the host’s
ability to tolerate a pathogen presence. Meanwhile, 2-AA silences
bacterial acute virulence functions [49] and dramatically increases
survival rates among infected mice (Fig. 1A). From an evolutionary
perspective, it is intriguing that P. aeruginosa would produce a QS
molecule that decreases its own virulence. However, this seemingly
counter-intuitive effect can ultimately be adaptive if it enables the
pathogen to secure long-term survival within its host. This
hypothesis is supported by data showing that 2-AA pretreatment
ameliorated the inflammatory response upon subsequent infection,
allowing infected mice to survive, and thus increasing the
pathogen’s fitness. 2-AA’s ability to render immune cells tolerant,
as observed in the present study, may mirror the mechanism by
which this pathogen avoids elimination and persists in chronic
infections. Elucidation of the molecular mechanisms involved in
enabling host organisms to tolerate persistent/chronic infections
may open new avenues for the development of diagnostics and
therapeutic strategies to treat chronic, persistent, and relapsing
infections.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations of the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Committee on the Ethics of Animal
Experiments at Massachusetts General Hospital (Permit Number:
2006N000093/2, for burn wound infection and 2005N000111, for
open wound infection). All procedures were performed under
ketamine/xylazine anesthesia, and every effort was made to
minimize suffering.
Bacterial strains and growth conditions
A P. aeruginosa strain known as Rif
R human clinical isolate
UCBPP-PA14 (commonly referred to as PA14) was used in the
present experiments [84], [85]. The bacteria were grown at 37uC
in Luria-Bertani (LB) broth under shaking and aeration or on
plates of LB agar containing appropriate antibiotics, unless
otherwise indicated. Overnight PA14 cultures were grown in
LB+rifampicin (50 mg/L) and diluted the following day in fresh
LB media.
Mouse mortality and CFU assays
A thermal injury mouse model [52] was used as described
previously [85] to assess bacterial pathogenicity in 6-wk-old CD1
mice (Charles River; Boston, MA). Following administration of
anesthesia, a full-thickness thermal burn injury involving 5–8% of
the total body surface area [52] was produced on the dermis of the
shaved mouse abdomen, and an inoculum of 5.0610
5 PA14 cells
in 100 ml of saline was injected intradermally into the burn eschar.
Mouse survival was subsequently assessed over the course of 10 d.
2-AA treated mice received a single intravenous (IV) injection of
2-AA (6.75 mg/kg mice) 6 h, 2 d, 4 d, 8 d, and 30 d prior to BI.
Mice treated with 4-AA (6.75 mg/kg mice), 2-NA (8.25 mg/kg
mice), MA (7.55 mg/kg mice), 3OH-2-AA (7.6 mg/kg mice),
and/or phosphate buffered saline (PBS; vehicle control) also
received a single IV injection, but 4 d prior to BI. All injected
compounds were purchased from Sigma-Aldrich (Saint Luis, MO).
To allow examination of bacterial persistence in the BI model,
we inoculated mice with 2610
3 PA14 cells to avoid mortality of
the control set. Animals were injected with 2-AA (6.75 mg/kg
mice) 4 d prior to BI. After 4 d, 2610
3 PA14 cells, in 100 mlo f
saline, were injected as and described above. Seven days post-BI,
CFU counts were assessed in 5–6 mice per group from muscle
samples obtained from underneath the burn. Samples were
homogenized in 1 ml of 16PBS. The samples were diluted and
plated on LB-agar plates containing rifampicin (50 mg/L).
Open wound model and CFU assays
The open wound mouse model was used as described in detail
elsewhere [54] to examine the long-term bacterial presence at the
chronic wound site. Briefly, 6-wk-old CD1 male mice (Charles
River; Boston, MA) were anesthetized by intraperitoneal injection
and their backs were shaved. Under aseptic conditions, a patch of
1.561.5 cm skin was surgically removed from the shaved back of
each mouse, exposing an area of collagen connective tissue above
the panniculus carnosus muscle. On the top of the surgical wound,
7610
3 bacterial cells were inoculated with 10 ml of 2-AA
(0.22 mg/kg mice) or an equal volume of vehicle. The surface of
the wound was dressed with a transparent and semipermeable
Tegaderm film to provide protection from non-experimental
bacterial contamination and to allow for daily inspection of the
wound. The mice were monitored for 11 d postinfection and CFU
counts were performed in 6 mice per group. Tissue samples from
the infected area of each mouse were homogenized in 1 ml of
PBS, diluted, and plated on LB-agar plates containing rifampicin
(50 mg/L).
Lung infection model and lung biopsy
We assessed the effects of 2-AA in a neonatal mouse lung
infection model [55] relevant to CF. A minimum inoculum of
1.5610
5 PA14 cells/animal is 100% lethal in this model. Mice
were pretreated with 2-AA 4 d before being infected and then
sacrificed 24 h, 48 h, or 72 h postinfection. The specimens were
fixed in 10% buffered formalin overnight and then, following a
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into 6-mm-thick sections. The sections were stained with hema-
toxylin & eosin (H-E) and evaluated by light microscopy. Lung
histopathology was assessed and the cytoarchitecture of the
infected animals was compared to that of controls.
In vivo cytokine analysis
Blood was collected 24 h post-BI from 4 mice in each group by
cardiac heart puncture. Serum was isolated and assayed by
multiplex sandwich enzyme-linked immunosorbent assay (ELISA)
(Quansys Biosciences, UT) containing nine antibodies (against IL-
1a, IL-1b, IL-2, IL-4, IL-6, IL-10, IL-12p70, TNF-a, and IFN-c).
The plate was imaged by cooled CCD camera and integrated
density values of the standard spots were used to generate standard
curves for the assayed proteins, and density values of the unknown
samples were calculated. This service was provided by Quansys
Biosciences, USA.
Cell culture
A Raw 264.7 murine macrophage cell line (American type
culture collection, Bethesda, MD) was maintained in Iscove’s
modified Dulbecco’s medium (IMDM, Gibco) supplemented with
10% fetal bovine serum (Gibco) containing penicillin/streptomy-
cin and gentamycin (Gibco) in the presence of 5% CO2 at 37uC.
The cells were seeded in T-75 tissue culture flasks (Falcon, USA)
and used between passages 2 and 3.
Preparation of stably transfected cells with luciferase
reporter plasmid
RAW 264.7 cells (5610
5 cells) were seeded in 60-mm dishes;
24 h later, a mixture of Lipofectamine LTX and Plus reagent
(Invitrogen, Grand Island, NY) and 2.5 mg of pGL4.-NF-kB
luciferase plasmid (a gift from Dr. Xavier’s Lab, MGH, Boston)
were added and then incubated for 6 h in serum-free medium.
The cells were then cultured in medium supplemented with serum
for an additional 72 h prior to being subjected to further analysis.
Medium containing 250 mg/ml hygromycin B (Roche Applied
Science, Basel, Switzerland) was used to select stable transfectants.
2-AA cell treatment
Stable RAW 264.7 cells carrying the NF-kB luciferase plasmid
were plated at a density of 10
5/ml in 24-well plates and grown
overnight at 37uCi n5 %C O 2. Cells in the treatment groups were
pretreated with 0.8 mM 2-AA for 48 h, and then 2-AA treated or
non-treated cells were washed with PBS and kept in fresh medium.
At various times, as indicated, the cells were stimulated with
0.2 mM, 0.4 mM, or 2 mM 2-AA. Similarly, cells were pretreated
with 4-AA (0.8 mM), LPS (100 ng/ml, Sigma-Aldrich), or PGN
(100 ng/ml, Sigma-Aldrich) for 48 h. After 48 h, the non-treated
or 4-AA/LPS/PGN pretreated cells were stimulated with 4-AA
(0.2 mM, 0.4 mM, or 2 mM), LPS (1 ng/ml), or PGN (10 ng/ml),
respectively.
Luciferase assay
After treatment, the stable Raw 264.7 cells were washed with
PBS. The cells were then lysed in the luciferase cell culture lysis
buffer provided with the Luciferase Assay Kit (Promega, Madison,
WI). After a brief vortexing, whole cell lysates were centrifuged at
4uC for 2 min at 12,000 rpm. Supernatant was collected and 20–
30 ml of the collected supernatant was added to 60–80 mlo f
luciferase substrate. Luminescence was measured in a Tecan F200
automated plate reader (Infinite F200, Tecan Group Ltd,
Ma ¨nnedorf, Switzerland) and expressed in relative light units
(RLU); each luciferase assay substrate reading was taken alone and
then with lysate. The value obtained for the luciferase assay
substrate without lysate was subtracted from the respective RLU
value for each lysate with luciferase assay reagent. The total
protein concentration in each lysate was determined with a
Bradford assay kit (Thermo Scientific, USA) and subsequently
used to normalize the luciferase activity data. Each assay was done
in triplicate within each trial and each trial was repeated three
times.
Western blot analysis
Cellular extracts were prepared in RIPA buffer (Cell Signaling
Technology, Boston, MA). Twenty micrograms of total protein
were added to Lamemli buffer, boiled for 5 min, resolved by SDS-
12% polyacrylamide gel electrophoresis (PAGE) in Tris/glycine/
SDS buffer (25 mM Tris, 250 mM glycine, 0.1% SDS), and
blotted onto PVDF membranes (Bio-Rad, Hercules, CA). The
membranes were blocked for 2 h in TBS-T (20 mM Tris-HCL,
150 mM NaCl, 0.1% Tween20) containing 5% non-fat milk. The
membranes were then washed three times in TBS-T and probed
overnight with rabbit antibodies specific for phospho-NF-kB p65,
phospho-extracellular regulated kinase (ERK)1/2, phospho-p38,
phospho-c-JUN N-terminal kinase (JNK)1/2 (Cell Signaling
Technology), NF-kB p65, Ik-Ba,I kB-b, or phospho-c-EBPb
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA) at a dilution of
1:1,000, and mouse anti-b-actin (Santa Cruz Biotechnology, Inc)
at a dilution of 1:2,000. Following three washes in TBS-T, the
membranes were incubated with secondary horse-radish peroxi-
dase (HRP)-conjugated goat anti-rabbit IgG (Santa Cruz Biotech-
nology, Inc) or goat anti-mouse IgG secondary antibodies
(Promega, Madison, WI), respectively, and then washed five times
in TBS-T. The bands were detected using SuperSignal West Pico
Chemiluminescent Substrate (Thermo Scientific, Rockford, IL),
according to the manufacturer’s instructions.
IP
For protein association assays, 100-mg aliquots of cytosolic
extracts were subjected to IP in TNT buffer [20 mM Tris-HCl,
pH 7.5, 200 mM NaCl, Triton 6100, 0.1 M phosphatase
inhibitor cocktails 1 and 2 (ingredients from Sigma-Aldrich)]. IP
was conducted at 4uC for 3 h with 2 mg of anti-c/EBPb or 2 mgo f
p65 (Santa Cruz Biotechnology) and 50 ml of Pierce protein A/G
agarose beads (Thermo Scientific). After washing three times with
PBS, the precipitated proteins were analyzed by PAGE and
western blotting.
Measurement of TNF-a, IFN-c, and TGF-b by ELISA
TNF-a, IFN-c, and TGF-b protein levels in culture superna-
tants were measured by ELISA using the Quantikine mouse TNF-
a and TGF-b kits (R & D Systems, Minneapolis, MN) and an
OptEIA mouse IFN-c kit (BD Biosciences Pharmingen, San
Diego, CA) according to the manufacturers’ instructions. Briefly,
the culture supernatants were added to anti-human TNF-a
monoclonal antibody-coated ELISA plates and incubated for 2 h
at room temperature. Following four washes, the detector
molecules (HRP-conjugated streptavidin and biotinylated anti-
human TNF-a) were added to plates and incubated for 2 h at
room temperature. The assay was developed with tetramethyl
benzidine (TMB) substrate reagent. Following a 20-min incuba-
tion at room temperature, the absorbance at 450 nm was
determined using a Sunrise plate reader (Tecan Group Ltd,
Ma ¨nnedorf, Switzerland). For the TGF-b and IFN-c assays, we
followed the same procedure as described above.
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Nuclear extracts were obtained from cells at various time points
using a Nuclear Extract kit (Active Motif, Carlsbad, CA). Briefly,
the cells were scraped in the presence of phosphatase inhibitors
into a hypotonic buffer and allowed to swell on ice, before being
treated with the non-ionic detergent nonidet-P40 and centrifuga-
tion (4uC, 12000 rpm, 15 min). The pellet was resuspended in
nuclear lysis buffer, gently rocked for 30 min at 4uC, and
centrifuged same as above. The Bradford protein assay was
performed on the resultant supernatants (nuclear extracts).
p65 and p50 nuclear binding assays were performed using a
NF-kB p65/p50 TransAM transcription factor assay kit (Active
Motif, Carlsbad, CA) according to the manufacturer’s protocol.
Briefly, the wells of a 96-well plate were pretreated with the NF-kB
consensus sequence oligonucleotides, and 40 ml of binding buffer
was added to the wells; 2-mg nuclear extract aliquots were brought
to a mass of 10 mg with lysis buffer and then added to the wells. A
1-mg aliquot of the provided Jurkat nuclear extract was used as a
positive control. Following 1 h of incubation, the wells were
washed three times with TBS-Tween. Primary antibody was
diluted 1:1500, added to the wells, and incubated for 1 h.
Following three washes, secondary HRP-conjugated anti-rabbit
antibody was diluted 1:1000 and added to the wells, incubated for
1 h. After four washes, the developing solution provided in the kit
was added. The development was allowed to proceed for 5 min
before the reaction was stopped with addition of the kit’s stop
solution. The absorbance was read on a spectrophotometer at
450 nm with a reference wavelength of 655 nm in a Sunrise plate
reader (Tecan Group Ltd, Ma ¨nnedorf, Switzerland)
MTT assay for cell cytotoxicity
The cytotoxicity of cells treated with 2-AA, 3-AA or 4-AA was
measured by MTT assay. MTT (3-[4, 5-dimethyl-2-thiazolyl]-2,
5-diphenyl-2H-tetrazolium bromide; Sigma-Aldrich) stock solution
(5 mg/ml PBS) was further diluted 1:5 in PBS. Two hundred
microliters of this working solution was added to the cells in a 96-
well culture plate for 2 h at 37uC under 5% CO2. The dissolved
MTT was allowed to convert to insoluble purple formazan via
mitochondrial activity in the cells during the 2-h incubation. The
supernatant was then removed and the cells were lysed for 10 min
with 95% isopropanol-5% formic acid. Absorbance of converted
dye was measured at 555 nm, with 690 nm as the reference
wavelength using a Sunrise plate reader (Tecan Group Ltd,
Ma ¨nnedorf, Switzerland).
Pharmacological inhibitors for signaling inhibition assay
To investigate the dependence of c/EBPb activation on ERK1/
2, 2-AA pretreated cells were incubated PD98059 (Sigma-Aldrich)
for 60 min and stimulated with 2-AA for different time periods.
For the cell signaling inhibition assay, cells were treated with NF-
kB inhibitors caffeic acid phenethyl ester (CAPE) (1.5 mM, Sigma-
Aldrich) or MG-132 (1 mM, Sigma-Aldrich) along with 2-AA.
Cells were treated actinomycin D (1 mM, Sigma-Aldrich) during
the 2-AA pre-treatment period.
Statistics
Wherever applicable, at least three independent experiments
were performed, and the data were analyzed using the Student’s t
test or a one-way analysis of variance (ANOVA). The animal data
were analyzed using the Kaplan-Meier survivability test. Bacterial
CFU counts were analyzed using the Kruskal-Wallis non-
parametric test. P values#0.05 were considered statistically
significant.
Supporting Information
Figure S1 2-AA activates NF-kB pathways and pro-
inflammatory cytokines in mouse macrophages. (A)
Mouse macrophages were incubated with 0.2 mM, 0.4 mM, or
2 mM 2-AA for the indicated time periods, and NF-kB activation
was monitored by luciferase assays. The results are expressed as
fold change compared to control cells. Mean values calculated
from three replicate experiments are depicted with SD error bars.
Macrophages were stimulated with 0.2-mM or 0.4-mM 2-AA at
the indicated time points. (B) IFN-c and (C) TNF-a secretion was
measured in cell supernatants by ELISA. Mean values calculated
from three replicate experiments are depicted with SD error bars.
*p,0.05 vs. naı ¨ve (Student’s t test).
(TIF)
Figure S2 Structures of 2-AA, the 2-AA metabolite 3OH-
2-AA, and the 2-AA analogs 4-AA, 2NA, and MA.
(TIF)
Figure S3 Effects of 2-AA on viability of mouse macro-
phages. MTT assay measuring cell viability in mouse macro-
phage cells after treatment with 0.2 mM, 0.4 mM or 0.8 mM 2-
AA for different time points, as indicated in the figure. SDs
(vertical bars) were calculated from three replicate experiments.
(TIF)
Figure S4 2-AA pretreated macrophages are broadly
hyporesponsive to pathogen associated molecules. Mac-
rophages were pretreated with 2-AA (0.8 mM), LPS (100 ng/ml),
or PGN (100 ng/ml) for 48 h and then stimulated with LPS
(1 ng/ml) or PGN (10 ng/ml) for 2 h. Activation of NF-kB
(expressed as fold change over background) upon stimulation with
LPS or PGN is shown. Mean values calculated from three
replicate experiments are depicted with SD error bars.
(TIF)
Figure S5 2-AA modulates NF-kBp65, p38, JNK, and
ERK phosphorylation in 2-AA pretreated mouse macro-
phages. Cells were pretreated with 2-AA (2-AA Pre) or medium
only (No Pre) for 48 h and subsequently stimulated with 2 mM 2-
AA for the indicated time periods. Western blotting of cellular
extracts with phospho-specific antibodies was used to reveal the
effects of 2-AA pretreatment on phosphorylation of (A) NF-kB p65,
(B) p38, (C) JNK1/2, and (D) ERK1/2 following 2-AA (2 mM)
stimulation. Loading was normalized relative to mouse b-actin.
(TIF)
Figure S6 4-AA pretreatment does not alter activation of
AP-1 in macrophages upon 4-AA stimulation. A TransAM
AP-1 transcription factor assay after a 48 h pretreatment with 4-
AA (0.8 mM) followed by stimulation with 4-AA, showing binding
of c-Fos (A) and c-Jun (B) to the AP-1 promoter. Mean values
calculated from three replicate experiments are depicted with SD
error bars (p,0.05, Student’s t test).
(TIF)
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